Literature DB >> 20087930

The prevalence of antibodies to adenovirus serotype 5 in an adult Indian population and implications for adenovirus vector vaccines.

Rajendra Pilankatta1, Tanu Chawla, Navin Khanna, Sathyamangalam Swaminathan.   

Abstract

In vivo gene delivery using human adenovirus serotype 5 (AdV5) vectors is being explored for vaccination purposes. The presence of anti-AdV5 antibodies in human serum arising from natural exposure to AdV5 can interfere potentially with and compromise the efficacy of rAdV5-based vaccine vectors. In this report, a collection of 114 sera from healthy adult Indian blood donors was analyzed for the presence of anti-AdV5 antibodies, using an AdV5 vector encoding the green fluorescent protein (GFP) to monitor the presence of anti-AdV5 neutralizing antibodies in human sera based on their ability to block virus entry into HeLa cells which express the Coxsackievirus-and-Adenovirus Receptor (CAR). In this assay all samples tested were positive for anti-AdV5 antibodies, with titers varying over a very wide range. It was also observed that these antibodies facilitated the uptake of the reporter AdV5 vector into the monocytic cell line U937 which does not express CAR, but expresses Fc receptors (FcRs) instead. These observations have implications for rAdV5-based vaccine development. J. Med. Virol. 82:407-414, 2010. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20087930     DOI: 10.1002/jmv.21721

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  18 in total

1.  A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs.

Authors:  Jin Huk Choi; Stephen C Schafer; Lihong Zhang; Gary P Kobinger; Terry Juelich; Alexander N Freiberg; Maria A Croyle
Journal:  Mol Pharm       Date:  2011-12-15       Impact factor: 4.939

2.  Optimized adenovirus-antibody complexes stimulate strong cellular and humoral immune responses against an encoded antigen in naive mice and those with preexisting immunity.

Authors:  Jin Huk Choi; Joe Dekker; Stephen C Schafer; Jobby John; Craig E Whitfill; Christopher S Petty; Eid E Haddad; Maria A Croyle
Journal:  Clin Vaccine Immunol       Date:  2011-11-16

Review 3.  Emerging targets and novel approaches to Ebola virus prophylaxis and treatment.

Authors:  Jin Huk Choi; Maria A Croyle
Journal:  BioDrugs       Date:  2013-12       Impact factor: 5.807

4.  Modeling pre-existing immunity to adenovirus in rodents: immunological requirements for successful development of a recombinant adenovirus serotype 5-based ebola vaccine.

Authors:  Jin Huk Choi; Stephen C Schafer; Lihong Zhang; Terry Juelich; Alexander N Freiberg; Maria A Croyle
Journal:  Mol Pharm       Date:  2013-08-19       Impact factor: 4.939

5.  Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity.

Authors:  Matthew J Johnson; Constantinos Petrovas; Takuya Yamamoto; Ross W B Lindsay; Karin Loré; Jason G D Gall; Emma Gostick; François Lefebvre; Mark J Cameron; David A Price; Elias Haddad; Rafick-Pierre Sekaly; Robert A Seder; Richard A Koup
Journal:  J Immunol       Date:  2012-05-14       Impact factor: 5.422

Review 6.  Advances and future challenges in adenoviral vector pharmacology and targeting.

Authors:  Reeti Khare; Christopher Y Chen; Eric A Weaver; Michael A Barry
Journal:  Curr Gene Ther       Date:  2011-08       Impact factor: 4.391

7.  Protection of adenovirus from neutralizing antibody by cationic PEG derivative ionically linked to adenovirus.

Authors:  Qin Zeng; Jianfeng Han; Dong Zhao; Tao Gong; Zhirong Zhang; Xun Sun
Journal:  Int J Nanomedicine       Date:  2012-02-27

8.  Comparison of two high-throughput assays for quantification of adenovirus type 5 neutralizing antibodies in a population of donors in China.

Authors:  Qiang Liu; Jianhui Nie; Weijin Huang; Shufang Meng; Baozhu Yuan; Dongying Gao; Xuemei Xu; Youchun Wang
Journal:  PLoS One       Date:  2012-05-24       Impact factor: 3.240

9.  Adenovirus delivered short hairpin RNA targeting a conserved site in the 5' non-translated region inhibits all four serotypes of dengue viruses.

Authors:  Anil Babu Korrapati; Gokul Swaminathan; Aarti Singh; Navin Khanna; Sathyamangalam Swaminathan
Journal:  PLoS Negl Trop Dis       Date:  2012-07-24

10.  Recombinant vaccines against T. gondii: comparison between homologous and heterologous vaccination protocols using two viral vectors expressing SAG1.

Authors:  Érica Araújo Mendes; Flavio G Fonseca; Bárbara M Casério; Janaína P Colina; Ricardo Tostes Gazzinelli; Braulia C Caetano
Journal:  PLoS One       Date:  2013-05-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.